Targeted Agents in AML (ABT199)

被引：0
|
作者：
Konopleva, Marina [1 ]
DiNardo, Courtney [1 ]
Pan, Rongqing Aaron [1 ]
Han, Lina [1 ]
Zhang, Qi [1 ]
Daver, Naval [1 ]
Kantarjian, Hagop [1 ]
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd 10, Houston, TX 77030 USA
来源：
ANNALS OF HEMATOLOGY | 2017年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S28 / S29
页数：2
相关论文
共 50 条
  • [21] Combined targeting of MCL1 with TG02 and BCL2 with ABT-737/ABT-199 as a strategy for eliminating AML cells
    Yu, N.
    Abdul-Aziz, A.
    Burrows, F.
    Russell, N.
    Seedhouse, C.
    Pallis, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 58 - 58
  • [22] MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells
    Wang, Qing
    Wan, Jiangbo
    Zhang, Wenhao
    Hao, Siguo
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2170 - 2180
  • [23] High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
    Bate-Eya, Laurel T.
    den Hartog, Ilona J. M.
    van der Ploeg, Ida
    Schild, Linda
    Koster, Jan
    Santo, Evan E.
    Westerhout, Ellen M.
    Versteeg, Rogier
    Caron, Huib N.
    Molenaar, Jan J.
    Dolman, M. Emmy M.
    ONCOTARGET, 2016, 7 (19) : 27946 - 27958
  • [24] ABT-199的合成方法评述
    张丽君
    广东化工, 2018, 45 (18) : 109 - 110
  • [25] ABT-199 partners with azacitidine to contest myeloid malignancies
    Wei, Andrew
    LEUKEMIA & LYMPHOMA, 2015, 56 (01) : 8 - 9
  • [26] The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia
    Itchaki, Gilad
    Brown, Jennifer R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (05) : 270 - 287
  • [27] ABT-199 in combination with rituximab or GS-9973: implications for macrophage phagocytosis and T cell mediated ABT-199 resistance in CLL patients
    Gamberale, Romina
    Enrique Elias, Esteban
    Belen Almejun, Maria
    Borge, Mercedes
    Podaza, Enrique
    Risnik, Denise
    Fernandez Grecco, Horacio
    Cabrejo, Maria
    Bezares, Fernando R.
    Giordano, Mirta
    Pose Cabarcos, Julio
    Colado, Ana
    LEUKEMIA & LYMPHOMA, 2017, 58 : 7 - 9
  • [28] Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199
    Akhtar, Sharoon
    Paulus, Aneel
    Samuel, Kelara
    Yousaf, Hassan
    Cogen, Davitte
    Roy, Vivek
    Sher, Taimur
    Foran, James M.
    Rivera, Candido E.
    Colon-Otero, Gerardo
    Ailawadhi, Sikander
    Chanan-Khan, Asher Alban
    BLOOD, 2015, 126 (23)
  • [29] Targeted therapies in AML: Evolving concepts for AML
    Serve, H.
    ONKOLOGIE, 2010, 33 : 183 - 184
  • [30] Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents
    Pratz, Keith W.
    Erba, Harry P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 : 16 - 22
12345